|
|
|
|
Small Stocks, Big Money™
|
|
Weekly Newsletter
|
|
|
|
|
|
|
|
Pentagon Backs NioCorp with Up to $10M for First U.S. Scandium Supply Chain
NioCorp’s (Nasdaq: NB) Elk Creek Resources has secured up to $10 million from the U.S. Department of Defense to fast-track America’s first domestic scandium mine-to-alloy production via its Nebraska-based Elk Creek Project. The funding, part of a broader “whole of government” approach that could unlock up to $800 million in U.S. Export-Import Bank financing, aims to accelerate scandium-aluminum alloy integration into defense aerospace systems, reducing reliance on China and positioning the U.S. as a global leader in critical mineral production.
|
|
|
|
GreenPower Lands $5M Contract to Launch New Mexico All-Electric School Bus Pilot
GreenPower Motor Company (Nasdaq: GP) signed a $5+ million deal with the State of New Mexico to roll out a two-year, six-bus pilot program showcasing its all-electric Nano BEAST, BEAST, and Mega BEAST school buses. The initiative, complete with charging infrastructure, driver and mechanic training, and a vehicle-to-grid evaluation, aims to test zero-emission performance, charging options, and grid resiliency, with the 300-mile-range Mega BEAST set to lead the industry in battery capacity and sustainability impact.
|
|
|
|
|
SolarMax Secures $127.3M Contract for 430 MWh Texas Battery Storage Project
SolarMax Technology (Nasdaq: SMXT) landed a $127.3 million EPC contract with Longfellow BESS I LLC to build a 430 MWh battery storage system in Pecos County, Texas, slated for completion by mid-2026. The project—supporting grid stability and peak-demand energy supply—marks a major expansion into utility-scale EPC services for SolarMax, which is also acquiring an 8% project stake as part of its strategy to diversify beyond residential solar.
|
|
|
|
|
|
|
Processa Pharmaceuticals Secures Strategic Investment, Explores Crypto Treasury Strategy
Processa Pharmaceuticals (Nasdaq: PCSA) received a strategic investment and is evaluating blockchain-based treasury strategies, including select yield-generating cryptocurrencies, to diversify capital sources and fund its Next Generation Cancer therapy pipeline. The move—advised by LifeSci Capital—aims to enhance financial flexibility, reduce shareholder dilution, and position Processa at the forefront of the biotech-fintech convergence.
|
|
|
|
|
Lantern Pharma’s Starlight Therapeutics Receives FDA Clearance for GBM Trial
Lantern Pharma’s (Nasdaq: LTRN) subsidiary Starlight Therapeutics has gained FDA clearance to launch a Phase Ib/2a trial of STAR-001 in combination with spironolactone for recurrent glioblastoma multiforme—a $3–$5 billion annual market with urgent unmet need. Backed by FDA Orphan and Fast Track designations, this AI-guided therapy leverages a novel synthetic lethality approach to target aggressive brain tumors and could deliver a long-awaited advance in GBM treatment.
|
|
|
Recent News
|
|
|
Unlock Smarter Investing with RedChat
Tired of sifting through endless filings? Let RedChat do the heavy lifting. Get real-time, data-driven insights on over 2,000 small-cap stocks—instantly. Save time, make informed decisions, and stay ahead of the market.
Access RedChat now, free of charge.
|
|
|
|
Recent Research Coverage Updates
| Company |
Rating |
Price Target |
Firm |
Report Date |
| FibroBiologics (Nasdaq: FBLG) |
Buy |
$16 |
D Boral |
July 29, 2025 |
| Connect Biopharma (Nasdaq: CNTB) |
Buy |
$7.5 |
Northland Securities |
July 23, 2025 |
| Connect Biopharma (Nasdaq: CNTB) |
Buy |
$4 |
Titan Partners |
July 17, 2025 |
| Connect Biopharma (Nasdaq: CNTB) |
Buy |
$7 |
H.C. Wainwright |
July 9, 2025 |
| FibroBiologics (Nasdaq: FBLG) |
Buy |
$16 |
D Boral |
July 9, 2025 |
| Alliance Entertainment (Nasdaq: AENT) |
Buy |
$10 |
Maxim |
July 1, 2025 |
| Lantern Pharma (Nasdaq: LTRN) |
Buy |
$25 |
Lake Street |
June 17, 2025 |
| Atossa Therapeutics (Nasdaq: ATOS) |
Buy |
$4 |
Craig Hallum |
June 5, 2025 |
| Alliance Entertainment (Nasdaq: AENT) |
Buy |
$8 |
ThinkEquity |
June 2, 2025 |
| Atossa Therapeutics (Nasdaq: ATOS) |
Buy |
$7.25 |
Ascendiant Capital |
April 20, 2025 |
| Enlivex Therapeutics (NASDAQ: ENLV) |
Buy |
$7 |
H.C. Wainwright |
March 24, 2025 |
| Lantern Pharma (Nasdaq: LTRN) |
Buy |
$15 |
ThinkEquity |
March 17, 2025 |
| Jupiter Neurosciences (Nasdaq: JUNS) |
Buy |
$30 |
Greenridge Global |
March 6, 2025 |
| Fathom Holdings (NASDAQ: FTHM) |
Buy |
$3.75 |
Roth |
March 3, 2025 |
| XORTX Therapeutics (Nasdaq: XRTX) |
Buy |
$14 |
AGP |
February 25, 2025 |
| Enlivex Therapeutics (NASDAQ: ENLV) |
Buy |
$13 |
D. Boral |
February 7, 2025 |
| Gorilla Technology Group (NASDAQ: GRRR) |
Buy |
$18 |
Northland Capital Markets |
January 22, 2025 |
| Gorilla Technology Group (NASDAQ: GRRR) |
Buy |
$3 |
ThinkEquity |
January 13, 2025 |
| Gorilla Technology Group (NASDAQ: GRRR) |
Buy |
$27 |
Alliance Global Partners |
January 2, 2025 |
| FibroBiologics (Nasdaq: FBLG) |
Buy |
$12 |
H.C. Wainwright |
October 30, 2024 |
| FibroBiologics (Nasdaq: FBLG) |
Buy |
$12 |
Maxim |
September 24, 2024 |
| FibroBiologics (Nasdaq: FBLG) |
Buy |
$11 |
Zachs Research |
June 24, 2024 |
|
|
|
|
|
Small Stocks, Big Money™ Podcast
The podcast features in-depth interviews with CEO’s from the top names in small-cap stocks, providing listeners with a unique perspective not found anywhere else.
Available on:
|
|
|
|
Upcoming Events
|
|
|
NASDAQ: NVA - Nova Minerals Limited
4:15pm Eastern
Nova Minerals Limited is a Gold, Antimony and Critical Minerals exploration and development company focused on advancing the Estelle Project, comprised of 513 km2 of State of Alaska mining claims, which contains multiple mining complexes across a 35 km long mineralized corridor of over 20 advanced Gold and Antimony prospects, including two already defined multi-million ounce resources, and several drill ready Antimony prospects with massive outcropping stibnite vein systems observed at surface.
|
|
|
|
NASDAQ: ENLV - Enlivex Therapeutics
4:15pm Eastern
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses.
|
|
|
|
NASDAQ: ASPI - ASP Isotopes
4:15pm Eastern
This exclusive event will provide investors with an opportunity to gain critical insights into ASP Isotopes' strategic initiatives and technological advancements.
|
|
|
|
Archived Events
|
|
|
NASDAQ: FATN - FatPipe
4:15pm Eastern
FatPipe, Inc. (Nasdaq: FATN) is a pioneer in secure, software-defined networking technologies that simplify and fortify enterprise connectivity.
|
|
|
|
NASDAQ: ATOS - Atossa Therapeutics
4:15pm Eastern
Atossa Therapeutics, Inc. (Nasdaq: ATOS) is a clinical-stage biopharmaceutical company advancing (Z)-endoxifen, a next-generation selective estrogen receptor modulator (SERM) with best-in-class potential across the breast cancer treatment spectrum.
|
|
|
|
NASDAQ: CNTB - Connect Biopharma Holdings
4:15pm Eastern
Connect Biopharma, headquartered in San Diego, California, is a clinical-stage biopharmaceutical company focused on advancing Rademikibart™, a potentially best-in-class next generation anti-interleukin-4-receptor alpha (IL-4Rα) antibody, to transform care in Asthma and COPD.
|
|
|
|
NASDAQ: GP - GreenPower Motor Company
4:15pm Eastern
GreenPower Motor Company is advancing the adoption of electric vehicles (EVs) by making all-electric buses and trucks affordable, durable and easy to deploy.
|
|
|
|
Quote of the Week
|
" Vast sums of money are being spent to gain advantages in speed."
|
|
|
|
|
RedChip TV
|
|
|
|
RedChip Highlights Sixty Degrees Pharma (NASDAQ: SXTP) & Aptevo Therapeutics Inc. (NASDAQ: APVO)
|
|
|
|
|
|
|
Order "Small Stocks, Big Money™ Today!
Dave Gentry's new book, Small Stocks, Big Money: Interviews With Microcap Superstars, is now available for pre-order. Published by Wiley Finance, this first-hand perspective and insider information on the fast world of microcap investing is now available for purchase.
|
|
|
|
|
|
|
Lesson of the Week
Dollar-cost average to lower your risk.
|
|
|
|
|
|
|
